U.S. markets open in 8 hours 43 minutes
  • S&P Futures

    3,674.00
    +9.50 (+0.26%)
     
  • Dow Futures

    30,007.00
    +75.00 (+0.25%)
     
  • Nasdaq Futures

    12,509.25
    +47.00 (+0.38%)
     
  • Russell 2000 Futures

    1,851.90
    +4.70 (+0.25%)
     
  • Crude Oil

    46.42
    +0.78 (+1.71%)
     
  • Gold

    1,843.00
    +1.90 (+0.10%)
     
  • Silver

    24.17
    +0.03 (+0.14%)
     
  • EUR/USD

    1.2146
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    0.9200
    -0.9200 (-100.00%)
     
  • Vix

    21.28
    -21.17 (-100.00%)
     
  • GBP/USD

    1.3444
    -0.0008 (-0.06%)
     
  • USD/JPY

    103.9400
    +0.0800 (+0.08%)
     
  • BTC-USD

    19,281.35
    +23.77 (+0.12%)
     
  • CMC Crypto 200

    378.63
    +4.22 (+1.13%)
     
  • FTSE 100

    6,490.27
    +26.88 (+0.42%)
     
  • Nikkei 225

    26,744.35
    -65.02 (-0.24%)
     

Phathom Pharmaceuticals to Host Virtual Investor Day

Phathom Pharmaceuticals
·1 min read
  • Event to be webcast on Monday, December 14, 2020 at 1:00 PM (ET)

FLORHAM PARK, N.J., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today confirmed it will host a virtual Investor Day on December 14, 2020 from 1 pm to 3:30 pm Eastern Time. Members of Phathom’s management team and gastroenterology key opinion leaders will provide updates on the company’s pipeline and commercial strategy.

Those interested in participating are invited to pre-register at http://bit.ly/PHAT-investor-day-2020. A replay of the webcast and the slide presentation will be available after the meeting on the News & Events section of the Phathom website at https://investors.phathompharma.com/.

About Phathom
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the Company’s website at www.phathompharma.com or follow the Company on LinkedIn at www.linkedin.com/company/phathompharma.

CONTACTS

Media Contact:
Nick Benedetto
1-877-742-8466
media@phathompharma.com

Investor Contact:
Todd Branning
1-877-742-8466
ir@phathompharma.com